News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


Lung cancer treatment takes another forward step

Note:  Embargoed until 6am, January 9, 2014

Media release

Lung cancer treatment takes another forward step            

Improvements in lung cancer treatment are set to continue with a PHARMAC decision to extend funding for erlotinib (Tarceva) from 1 January 2014.

Erlotinib and another similar drug gefitinib (Iressa) are tyrosine kinase inhibitors (TKIs) that have changed the way aggressive lung cancer is treated, and improved the prospects of people diagnosed with lung cancer.

Ministry of Health data shows that while colon cancer, prostate cancer, breast cancer and melanoma are most commonly diagnosed in New Zealand, the leading cause of cancer deaths is lung cancer.

TKIs are part of a new wave of targeted cancer medicines, which are particularly effective for patients with lung cancer that harbour a particular genetic sequence. Patients are identified using a diagnostic test called epidermal growth factor receptor (EGFR) testing. For people with this type of disease, targetted TKIs offer more effective, less toxic, and more convenient treatment.

Erlotinib was the first TKI to be funded in 2010, and since then access has been improved and widened so that from 1 January 2014, both erlotinib and gefitinib are funded for people who are newly diagnosed and who have not previously had platinum-based chemotherapy.

PHARMAC Deputy Medical Director Dilky Rasiah says the impact of the change in lung cancer treatments is becoming more apparent.

“For patients identified through testing, the TKIs have three major advantages over the chemotherapy treatments they are replacing,” she says.

“Firstly, and most importantly, they are more effective treatments for some patients. Usually when a new cancer drug or class of drugs becomes available, a three or four month improvement is considered a good advance. For the TKIs, the data show that the improvement in disease-free survival, the main marker for cancer treatment benefit, is 9-12 months. So this really is a significant improvement in lung cancer outcomes in New Zealand.”

“In addition to being more effective, TKIs don’t have a lot of the nasty side-effects compared with traditional platinum-based chemotherapy, which is very difficult for patients to tolerate. This means more people can maintain a good quality of life and continue on their treatment for longer, whereas previously people may have had to stop, or skip doses due to side effects, so again we get better outcomes.”


“The other benefit is convenience for patients. The TKIs are oral tablets that patients can collect from their pharmacy and take at home. By comparison, people had to make several journeys to a cancer treatment centre to receive an infusion of traditional chemotherapy. This could be difficult for people living some distance from a cancer treatment centre, and means people being treated with TKIs for cancer can carry on with life, and be with their families at a time when they need support.

“So, in short, having TKIs is a major advance in making effective treatment more available and convenient for patients.”

Dr Rasiah says the benefits also extend to other cancer patients not directly taking TKIs. Because the drugs can be taken at home, this frees up the hospital infusion services for other people needing cancer treatment, so that overall more people can receive funded cancer treatments in public hospitals.

PHARMAC’s decision to widen access to erlotinib, to become a first-line treatment for lung cancer, follows a price reduction by the supplier Roche.

ENDS

© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 

Eddie Izzard: UK Comedy Legend Returns

Hailed as one of the foremost stand up comedians of his generation. Star of stage and screen. Tireless supporter of charity. Runner. Political campaigner. Fashion Icon... February 2015, Eddie Izzard will bring his massive FORCE MAJEURE world tour to New Zealand with tickets going on sale at 10am on Tuesday 28th October. More>>

Festival Starts 28 Oct: Improv Fest Makes Up New Show

For any other festival, finding out less than two weeks from showtime that half the cast of a programmed show can’t make it to New Zealand would be a nightmare. Instead, the New Zealand Improv Festival Director Jennifer O’Sullivan saw an opportunity ... More>>

NZ Music Awards Finalists: Lorde, Sol3 Mio Top 2014 Tuis Charge

Lorde has taken the music world by storm during the past year and she co-leads the 2014 Tui charge with five finalist spots. Joining her is newcomer family opera trio, Sol3 Mio. They are followed closely by Ladi6 and David Dallas, both up for four awards each. More>>

From 'Luther' Creator: Major New Zealand Crime Series For BBC

Libertine Pictures and writer Neil Cross have teamed up with leading international TV producer Carnival Films to develop a major new crime series set in Rotorua. Libertine will develop the contemporary drama series with Carnival, producer of internationally-acclaimed British period drama Downton Abbey, for the BBC. More>>

ALSO:

Family Statement: Death Of Ewen Gilmour

“Ewen was a much loved and cherished member of our family, he was a larger than life character and by his very nature was kind, generous and always giving of his time to those who asked for his help." More>>

ALSO:

Auckland: St. Jerome's Laneway Festival - Line-Up Announced

Traversing seven cities and three countries, the festival has well and truly settled into its home in each state. From the grassy knolls and towering silos at home in Auckland, to the sparkling backdrop of the Maribyrnong... More>>

Scoop Review Of Books: No Longer An Island

Simon Nathan reviews 'Zealandia: Our Continent Revealed': The idea that New Zealand is part of a large submerged continent is not new... There was renewed interest in the extent of offshore New Zealand from the 1970s onwards with the start of offshore drilling for oil and gas, and this was given impetus by a UN agreement which allowed countries to claim an Extended Continental Shelf (ECS). More>>

Art: Simon Denny Recreates Kim Dotcom’s Personal Effects

Who owns what? How has the internet changed our relation to the world? These are two of the many questions Simon Denny raises in the latest exhibition at the Adam Art Gallery, opening on Saturday 4 October. More>>

ALSO:

Get More From Scoop

 
 

LATEST HEADLINES

 
 
 
 
Health
Search Scoop  
 
 
Powered by Vodafone
NZ independent news